share_log

HC Wainwright & Co. Maintains Buy on Addex Therapeutics, Lowers Price Target to $15

Benzinga Real-time News ·  May 31, 2022 06:28

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Addex Therapeutics (NASDAQ:ADXN) with a Buy and lowers the price target from $21 to $15.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment